Arrhythmias & electrophysiology

Rationale and Design of the BradycArdia paCemaKer with AV interval modulation for Blood prEssure treAtmenT (BACKBEAT) Pivotal Trial

Am Heart JPublished global, multicenter, prospective, randomized, double-blinded clinical trial

Study context

Population
Patients implanted with, or scheduled to be implanted with, a dual-chamber pacemaker who have uncontrolled hypertension (office systolic blood pressure (oSBP) ≥135 mmHg and ambulatory systolic blood pressure (aSBP) ≥130 mmHg despite stable medical therapy)planned enrolment across up to 130 sites
Participants
≈316 patients
Planned comparison
Atrioventricular interval modulation (AVIM) ON vs AVIM OFF
Primary endpoint
Between-group difference in the change of mean 24-hour aSBP from baseline
Follow-up
3 months post-randomization

No results yet. This paper sets out the design of a trial; its results are to come.

Original publication

Rationale and Design of the BradycArdia paCemaKer with AV interval modulation for Blood prEssure treAtmenT (BACKBEAT) Pivotal Trial. Am Heart J. Published 11 November 2026. doi:10.1016/j.ahj.2026.107652

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.